☆ 4.6 Editorial Material

Estimation of glomerular filtration rate in cardiorenal patients: a step forward

CLINICAL KIDNEY JOURNAL (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Cystatin C-Based Equation to Estimate GFR without the Inclusion of Race and Sex

H. Pottel et al.

Summary: The study developed a cystatin C-based equation (EKFC eGFRcys) to estimate glomerular filtration rate (GFR). This equation had similar accuracy to a creatinine-based equation (EKFC eGFRcr) and outperformed other commonly used equations. Furthermore, taking the arithmetic mean of EKFC eGFRcr and EKFC eGFRcys further improved the accuracy of GFR estimation.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Editorial Material Urology & Nephrology

Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association

Alberto Ortiz et al.

Summary: The European Society of Cardiology's 2021 guideline on cardiovascular disease prevention has important implications for CV risk screening and kidney health. It emphasizes the need for categorizing individuals based on established conditions such as atherosclerotic CVD, diabetes, hypercholesterolemia, or chronic kidney disease. The inclusion of albuminuria as a step in CVD risk assessment should change clinical practice. Further research is needed to determine the optimal method for assessing CV risk in the general population, including the role of systematic screening for CKD.

CLINICAL KIDNEY JOURNAL (2023)

Add to Collection

Article Cardiac & Cardiovascular Systems

Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association

Connie W. Tsao et al.

Summary: This article introduces the latest statistics on heart disease, stroke, and cardiovascular risk factors published by the American Heart Association in conjunction with the National Institutes of Health. The Statistical Update includes data on a range of clinical heart and circulatory disease conditions and their associated outcomes. It serves as a critical resource for the general public, policymakers, healthcare professionals, researchers, and others seeking the best available data.

CIRCULATION (2022)

Add to Collection

Review Urology & Nephrology

Kidney and heart failure outcomes associated with SGLT2 inhibitor use

Annemarie B. Van der Aart-van der Beek et al.

Summary: Sodium-glucose co-transporter 2 (SGLT2) inhibitors are effective drugs for treating chronic kidney disease and heart failure, not only in patients with diabetes but also in other subgroups. SGLT2 inhibitors can also reduce the risk of anemia and hyperkalemia in CKD patients.

NATURE REVIEWS NEPHROLOGY (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

Frank L. J. Visseren et al.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)

Add to Collection

Article Endocrinology & Metabolism

Overestimation of glomerular filtration rate calculated from creatinine as compared with cystatin C in patients with type 2 diabetes receiving sodium-glucose cotransportor 2 inhibitors

Pensiri Choosongsang et al.

Summary: This cross-sectional study aimed to compare eGFRcr and eGFRcys in patients with type 2 diabetes receiving and not receiving SGLT2 inhibitors. The results showed a significant difference between eGFRcr and eGFRcys in the SGLT2 inhibitors group, with eGFRcr being higher.

DIABETIC MEDICINE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis

Arnaud D. Kaze et al.

Summary: The study showed that the use of SGLT2i in patients with DKD is associated with reduced risks of MACE, kidney outcomes, HHF, and death. There is limited data on the associations between SGLT2i and safety outcomes, indicating the need for further research.

CARDIOVASCULAR DIABETOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Precision Nephrology in Patients with Diabetes and Chronic Kidney Disease

Michele Provenzano et al.

Summary: Diabetic kidney disease is a major contributor to kidney failure and cardiovascular risk in diabetic patients. Developing novel biomarkers for predicting patient risk and treatment response is essential for improving care.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Urology & Nephrology

Cystatin C-based estimated GFR performs best in identifying individuals with poorer survival in an unselected Chinese population: results from the China Health and Retirement Longitudinal Study (CHARLS)

Cheng Zhu et al.

Summary: A decline in eGFR using various equations is associated with increased mortality over 2 years, with CKD-EPIcys showing the best discriminative power. Using the CKD-EPIcys equation improves overall risk classification and predictive ability for mortality.

CLINICAL KIDNEY JOURNAL (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

Biomarkers in Cardiorenal Syndrome and Potential Insights Into Novel Therapeutics

Edmund Y. M. Chung et al.

Summary: Heart and kidney failure often coexist and result in high morbidity and mortality rates. This complex bi-directional dysfunction, known as cardiorenal syndrome, can be caused by acute or chronic dysfunction in either organ or systemic diseases. Traditional biomarkers are limited in their ability to provide early and accurate diagnosis of cardiorenal syndrome. New biomarkers have the potential to assess the relative roles of various pathophysiological pathways and aid in diagnosis and treatment.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials

Runzhou Pan et al.

Summary: The meta-analysis found that SGLT-2 inhibitors have positive effects on body composition in patients with T2DM, including weight reduction, decreased body fat, waist circumference, and fat mass, but also have adverse effects on muscle mass reduction.

PLOS ONE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses

Liam Gaziano et al.

Summary: The study results suggest that mild-to-moderate kidney dysfunction is causally related to the risk of coronary heart disease in people without manifest cardiovascular disease or diabetes.

CIRCULATION (2022)

Add to Collection

Review Medicine, General & Internal

Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials

Wan-Chuan Tsai et al.

Summary: This study assessed the cardiovascular and renal efficacy and safety of SGLT2 inhibitors in patients without diabetes. The results showed that SGLT2 inhibitors had favorable effects on cardiovascular and renal outcomes, but increased the risk of urinary tract and genital infections in these patients.

BMJ OPEN (2022)

Add to Collection

Article Medicine, General & Internal

Assessment of Cystatin C Level for Risk Stratification in Adults With Chronic Kidney Disease

Jennifer S. Lees et al.

Summary: This study suggests that eGFRcys is more sensitive and specific for cardiovascular disease and mortality risks in mild chronic kidney disease, while eGFRcr fails to effectively predict high-risk individuals.

JAMA NETWORK OPEN (2022)

Add to Collection

Review Urology & Nephrology

Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR

Debbie C. Chen et al.

Summary: Cystatin C is a reliable and accurate marker for kidney function, recommended for estimating glomerular filtration rate and diagnosing CKD. However, it poses challenges in clinical practice.

KIDNEY360 (2022)

Add to Collection

Review Urology & Nephrology

Sarcopenia in chronic kidney disease: what have we learned so far?

Alice Sabatino et al.

Summary: Sarcopenia, initially defined as muscle loss in elderly by Irwin Rosenberg in 1988, has now evolved to encompass not only muscle mass loss but also strength and physical performance decline in consensus papers. In CKD, sarcopenia is prevalent not just due to aging, but also accelerated protein breakdown from the disease and dialysis, associated with worse clinical outcomes.

JOURNAL OF NEPHROLOGY (2021)

Add to Collection

Review Medicine, Research & Experimental

Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review

Oliver Darlington et al.

Summary: This study evaluated the risks of cardiovascular morbidity and mortality in patients with chronic kidney disease, finding that the risk of adverse clinical outcomes increases with the severity of CKD and albuminuria. This is associated with substantial additional costs and healthcare resource utilization, highlighting the importance of early diagnosis and proactive management of CKD to reduce the burden on healthcare resources.

ADVANCES IN THERAPY (2021)

Add to Collection

Article Urology & Nephrology

The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Michael G. Shlipak et al.

Summary: Chronic kidney disease (CKD) is a significant global burden associated with higher morbidity and mortality, especially among individuals with lower socioeconomic status. Despite the availability of guidelines for evaluating and managing early CKD, there is still a lack of consensus on prioritizing early identification and intervention for CKD without incentives or quality measures.

KIDNEY INTERNATIONAL (2021)

Add to Collection

Review Urology & Nephrology

Assessment of kidney function: clinical indications for measured GFR

Natalie Ebert et al.

Summary: The article discusses the limitations of estimating glomerular filtration rate (GFR) using serum creatinine and proposes possible solutions such as using cystatin C or an exogenous marker for direct measurement. Various clinical scenarios where creatinine-based GFR estimation may be invalid are highlighted, emphasizing the importance of personalized medicine and the need for standardized GFR procedures.

CLINICAL KIDNEY JOURNAL (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardiovascular Disease in Chronic Kidney Disease Pathophysiological Insights and Therapeutic Options

Joachim Jankowski et al.

Summary: Patients with chronic kidney disease face an increased risk of cardiovascular events, with advanced CKD stages significantly elevating the risk. Cardiovascular events, rather than end-stage kidney disease, are the leading cause of death in this high-risk population, and CKD causes a proinflammatory state that affects the cardiovascular system.

CIRCULATION (2021)

Add to Collection

Article Medicine, General & Internal

Race, Genetic Ancestry, and Estimating Kidney Function in CKD

C. Hsu et al.

Summary: The study found that using serum creatinine levels to estimate GFR without taking race (or genetic ancestry) into account led to systematic misclassification. Estimating GFR with cystatin C produced similar results while eliminating negative consequences of race-based approaches.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, Research & Experimental

Mild impairment of renal function (shrunken pore syndrome) is associated with increased risk of a future first-ever myocardial infarction in women

Elisabet Soderstrom et al.

Summary: Lower eGFR(cystatin C)/eGFR(creatinine) ratio in women is associated with a higher risk of future MI, suggesting it may be a valuable biomarker for cardiovascular disease risk. Conversely, a high eGFR(creatinine) is independently associated with increased future MI risk in men.

SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

The Shrunken pore syndrome is associated with poor prognosis and lower quality of life in heart failure patients: the HARVEST-Malmo study

Liana Xhakollari et al.

Summary: This study found an association between 'Shrunken pore syndrome' (SPS) and increased risk of death, 30 day rehospitalization, as well as impaired health-related quality of life in heart failure patients.

ESC HEART FAILURE (2021)

Add to Collection

Article Medicine, General & Internal

Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017

Boris Bikbov et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Sodium-Glucose Cotransporter 2 Inhibitors and Kidney Outcomes: True Renoprotection, Loss of Muscle Mass or Both?

Adrian Post et al.

JOURNAL OF CLINICAL MEDICINE (2020)

Add to Collection

Article Endocrinology & Metabolism

Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use

Yuka Goto et al.

ENDOCRINE CONNECTIONS (2020)

Add to Collection

Review Medical Laboratory Technology

Shrunken pore syndrome - a common kidney disorder with high mortality. Diagnosis, prevalence, pathophysiology and treatment options

Anders Grubb

CLINICAL BIOCHEMISTRY (2020)

Add to Collection

Review Biochemistry & Molecular Biology

Muscle Wasting and Sarcopenia in Heart Failure-The Current State of Science

Alessia Lena et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)

Add to Collection

Article Medicine, General & Internal

Contribution of cystatin C- and creatinine-based definitions of chronic kidney disease to cardiovascular risk assessment in 20 population-based and 3 disease cohorts: the BiomarCaRE project

Dietrich Rothenbacher et al.

BMC MEDICINE (2020)

Add to Collection

Article Endocrinology & Metabolism

Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study

Takashi Sasaki et al.

JOURNAL OF DIABETES INVESTIGATION (2019)

Add to Collection

Article Medicine, General & Internal

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

V. Perkovic et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Endocrinology & Metabolism

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial

Ofri Mosenzon et al.

LANCET DIABETES & ENDOCRINOLOGY (2019)

Add to Collection

Review Hematology

Atherosclerosis in Chronic Kidney Disease More, Less, or Just Different?

Jose M. Valdivielso et al.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease

Jennifer S. Lees et al.

NATURE MEDICINE (2019)

Add to Collection

Article Urology & Nephrology

Evaluation of discriminative capacity of two formulas of CKD-EPI to predict complications after the first episode of heart failure with preserved ejection fraction

Dmitry Shchekochikhin et al.

INTERNATIONAL JOURNAL OF NEPHROLOGY AND RENOVASCULAR DISEASE (2019)

Add to Collection

Article Peripheral Vascular Disease

Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes

Seigo Sugiyama et al.

JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS (2018)

Add to Collection

Article Medicine, General & Internal

Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease

Teruki Miyake et al.

OPEN MEDICINE (2018)

Add to Collection

Review Endocrinology & Metabolism

Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition

Volker Vallon et al.

DIABETOLOGIA (2017)

Add to Collection

Article Gastroenterology & Hepatology

Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus

Yuya Seko et al.

HEPATOLOGY RESEARCH (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study

Jiang He et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)

Add to Collection

Article Medicine, Research & Experimental

Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study

Hiroshi Tobita et al.

CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardiovascular Health in African Americans A Scientific Statement From the American Heart Association

Mercedes R. Carnethon et al.

CIRCULATION (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study

Ryotaro Bouchi et al.

CARDIOVASCULAR DIABETOLOGY (2017)

Add to Collection

Article Endocrinology & Metabolism

Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy

Chiho Yamamoto et al.

ENDOCRINE JOURNAL (2016)

Add to Collection

Article Peripheral Vascular Disease

Association of cystatin C with heart failure with preserved ejection fraction in elderly hypertensive patients: potential role of altered collagen metabolism

Ana Huerta et al.

JOURNAL OF HYPERTENSION (2016)

Add to Collection

Article Medicine, General & Internal

The heart and vascular system in dialysis

Christoph Wanner et al.

LANCET (2016)

Add to Collection

Article Medicine, General & Internal

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Urology & Nephrology

Cause of Death in Patients with Reduced Kidney Function

Stephanie Thompson et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)

Add to Collection

Article Medical Laboratory Technology

Long-term Prognostic Value for Patients with Chronic Heart Failure of Estimated Glomerular Filtration Rate Calculated with the New CKD-EPI Equations Containing Cystatin C

Elisabet Zamora et al.

CLINICAL CHEMISTRY (2014)

Add to Collection

Article Medicine, General & Internal

Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention

Ron T. Gansevoort et al.

LANCET (2013)

Add to Collection

Article Medicine, General & Internal

Cystatin C versus Creatinine in Determining Risk Based on Kidney Function

Michael G. Shlipak et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Medicine, General & Internal

Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C

Lesley A. Inker et al.

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Urology & Nephrology

Cystatin C Identifies Chronic Kidney Disease Patients at Higher Risk for Complications

Carmen A. Peralta et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)

Add to Collection

Editorial Material Urology & Nephrology

The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report

Andrew S. Levey et al.

KIDNEY INTERNATIONAL (2011)

Add to Collection

Review Urology & Nephrology

Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)

Charles A. Herzog et al.

KIDNEY INTERNATIONAL (2011)

Add to Collection

Article Anthropology

Ethnicity-Related Skeletal Muscle Differences Across the Lifespan

Analiza M. Silva et al.

AMERICAN JOURNAL OF HUMAN BIOLOGY (2010)

Add to Collection

Article Medicine, General & Internal

Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis

Kunihiro Matsushita et al.

LANCET (2010)

Add to Collection

Article Medicine, General & Internal

A New Equation to Estimate Glomerular Filtration Rate

Andrew S. Levey et al.

ANNALS OF INTERNAL MEDICINE (2009)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cystatin C and risk of heart failure in the Physicians' Health Study (PHS)

Luc Djousse et al.

AMERICAN HEART JOURNAL (2008)

Add to Collection

Article Medicine, General & Internal

Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease

Michael G. Shlipak et al.

ANNALS OF INTERNAL MEDICINE (2006)

Add to Collection

Article Medicine, General & Internal

Cystatin C concentration as a risk factor for heart failure in older adults

MJ Sarnak et al.

ANNALS OF INTERNAL MEDICINE (2005)

Add to Collection

Article Cardiac & Cardiovascular Systems

Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community

G Manjunath et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)

Add to Collection

Article Urology & Nephrology

Serum cystatin C is superior to serum creatinine as a marker of kidney function: A meta-analysis

VR Dharnidharka et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.